Fig. 7 | Scientific Reports

Fig. 7

From: Targeting ADAM17 to dampen dendritic cell-mediated type 2 immune responses and airway inflammation associated with allergic asthma

Fig. 7

Inhaled ADAM17 inhibitor, 2155-17, prevented HDM-induced asthma exacerbation. (A) Experimental layout of ADAM17 inhibitor (2155-17) treatment in vivo. WT mice were sensitized and challenged with HDM to induce experimental asthma and were concurrently received intranasal ADAM17 inhibitor 2155-17 (200 μg per mouse) or PBS (Veh) on days 8, 10, 12, and 14 before endpoint assessment on day 16. (B) Enumeration of total inflammatory cells, CD11b + Siglec-F + eosinophils, and CD11b + Ly-6G + neutrophils in BAL (left) and lung (right). The bar graph represents (C) serum levels of HDM-specific IgG1 and IgE, and the scatter plot shows (D) lung cytokine levels from local application of 2155-17 in asthmatic mice. Each circle represents individual mice. (E) Representative histologic lung sections of 2155-17- and PBS treated asthmatic lung stained with PAS. Scale bars, 100 μm for × 100 and 50 μm for × 400 images. Results are expressed as mean + / − SEM and represent one of the two independent experiments; n = 4 to 7 mice per group; *p < 0.05 unpaired Student’s t-test.

Back to article page